Main Page
  
1-609-841-1201          

Main Page

Русский
English
 
 
The CureLab Oncology team is currently conducting  Phase I of  Clinical Trial of the  anti-cancer vaccine Elenagen® .  The vaccine showed no toxicity at therapeutic doses.  A suspension of tumor growth  and metastatic processes is observed  in a number of patients being treated by the vaccine during the trial .
For any inquiries, please contact: , or  +1-609-841-1201 . For more detailed information on the clinical trials program, please follow this link:

Clinical trials
 



The CureLab Oncology team has gained approval from the Russian Federation Ministry of Health for clinical trials of its anti-cancer vaccine Elenagen® and started Phase I.
The CureLab Oncology team is currently conducting  Phase I of  Clinical Trile of the  anti-cancer vaccine Elenagen® .  The vaccine showed no toxicity at therapeutic doses.A suspension of tumor growth  and metastatic processes is observed  in number of patients been treated by the vaccine during the trile
Patients with solid tumors are currently being recruited to participate in the clinical trials. For any inquiries, please contact:, or +1-609-841-1201. For more detailed information on the clinical trials program, please follow this link:

Clinical trials

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics. CureLab Oncology is committed to creating a family of revolutionary therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product is an anti-cancer DNA vaccine, Elenagen® , that acts on a broad spectrum of primary tumors and metastatic processes. Elenagen® has successfully passed a full range of legally required preclinical toxicology tests and demonstrated significant anti-cancer potency in pilot studies with spontaneous tumors in dogs.
  
 
Разработка SEO-Online
Работает на Amiro.CMS - Free